REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

10/07/2020 15:10

RNS Number : 7173S
  
GlaxoSmithKline PLC
  
10 July 2020
  
 

GlaxoSmithKline plc (the 'Company')
Transaction notification



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms E Walmsley




b)


Position/status


Chief Executive Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£16.1010


22


























d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price








e)


Date of the transaction


2020-07-09




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Connor




b)


Position/status


President, Global Vaccines




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£16.1010


69


























d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price








e)


Date of the transaction


2020-07-09




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Conrad




b)


Position/status


SVP, Human Resources




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£16.1010


2


























d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price








e)


Date of the transaction


2020-07-09




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


SVP & General Counsel




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£16.1010


1


























d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price








e)


Date of the transaction


2020-07-09




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics & Compliance




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£16.1010


15


























d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price








e)


Date of the transaction


2020-07-09




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms S Jackson




b)


Position/status


SVP, Global Communications and CEO Office




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£16.1010


64


























d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price








e)


Date of the transaction


2020-07-09




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Jackson




b)


Position/status


PCA of Ms S Jackson (SVP, Global Communications and CEO Office)




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£16.1010


23


























d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price








e)


Date of the transaction


2020-07-09




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr L Miels




b)


Position/status


President, Global Pharmaceuticals




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£16.1010


3


























d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price








e)


Date of the transaction


2020-07-09




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Redfern




b)


Position/status


Chief Strategy Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£16.1010


77


























d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price








e)


Date of the transaction


2020-07-09




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Simard




b)


Position/status


President, Pharmaceuticals Supply Chain




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£16.1010


22


























d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price








e)


Date of the transaction


2020-07-09




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr P C Thomson




b)


Position/status


President, Global Affairs




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£16.1010


46


























d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price








e)


Date of the transaction


2020-07-09




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Waterhouse




b)


Position/status


Chief Executive Officer of ViiV Healthcare




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£16.1010


63


























d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price








e)


Date of the transaction


2020-07-09




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms V Whyte




b)


Position/status


Company Secretary




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£16.1010


57


























d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price








e)


Date of the transaction


2020-07-09




f)


Place of the transaction
 


London Stock Exchange (XLON)



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHZBLFFBDLBBBE